Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, and PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration to optimise size selection for long-read sequencing workflows. PacBio has qualified Yourgene’s LightBench® instrument for size selection of long DNA fragments, enabling high yields for HiFi sequencing data.

Yourgene’s LightBench is an automated electrophoresis instrument, powered by Ranger® Technology. This platform uses a patent-protected, machine-vision algorithm to interpret and control gel electrophoresis in real time. It delivers accurate size selection for human genomic DNA and includes the ability to perform fragment length analysis for additional quality control.

PacBio HiFi sequencing is a single-molecule real-time (SMRT®) sequencing technology. It produces long (1,000 to 20,000+ bases), accurate reads with uniform genomic coverage and native methylation detection for use in applications such as whole genome reconstruction, haplotype phasing, detection of large and complex variants, and epigenetics.

A new Technical Note was released today for PacBio customers titled “Size selection of PacBio SMRTbell® libraries with the LightBench® instrument from Yourgene Health.” The Yourgene LightBench instrument is compatible with the Revio system. The automated LightBench workflow optimises walk away time, offering a scalable size selection solution for the preparation of PacBio SMRTbell sequencing libraries. Results from the initial study* assessing two fragment lengths in 84 human genomic DNA samples from frozen blood for library preparation showed consistent yields for 8 kb or 10 kb size and a zero percent failure rate.

Matthew Nesbitt, Co-Founder of Ranger Technology, at Yourgene Health, said: “PacBio HiFi sequencing technology is a game changer for whole genome applications. High-resolution size selection is crucial to maximising data yields from long-read sequencing and Yourgene is proud to offer researchers a precise and scalable solution with the LightBench.”

*Download the “Size selection of PacBio SMRTbell® libraries with the LightBench® instrument from Yourgene Health.” Technical Note to learn more: https://www.pacb.com/wp-content/uploads/Technical-note-Size-selection-of-PacBio-SMRTbell-libraries-with-the-LightBench-instrument-from-Yourgene-Health.pdf

Visit https://yourgenehealth.com/our-products/instruments/lightbench/ for further information about Yourgene’s LightBench instrument, and https://www.pacb.com/3rd-party-compatible-products/ for details of the PacBio Compatible programme.

Yourgene will also be attending the Association of Molecular Pathology (AMP) 2023 Annual Meeting & Expo in Salt Lake City, UT from 14–18 November. Visit booth #425 to learn more.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

OCSiAl’s exceptional graphene nanotubes -based solution addresses these issues, ushering in a new era of silicone PSA technology. The user-friendly nanotube dispersion TUBALLTM MATRIX 617 results in excellent electrical conductivity combined with more than 90% transparency in a wide range of peeling-strength PSA films.
“Our latest study is the result of six years of focused research, delivering a practical model that allows users to predict metabolic pathways for a wide range of drug-like compounds. Thanks to our carefully curated datasets and our signature reactivity-accessibility approach, we have managed to build accurate isoform-specific regioselectivity models for the important Phase I and II enzyme families” Dr Mario Öeren, Principal Scientist, Optibrium said
The Nevisense System is a first-of-its-kind AI-driven technology that uniquely addresses the complexities of point-of-care detection of the deadliest form of skin cancer by providing clinicians with advanced analysis of irregular moles during routine skin checks.
"We are pleased to enter into this collaboration with Lycia Therapeutics, extending our service footprint to the area of extracellular protein degradation. We believe Lycia's leveraging of our antibody discovery capabilities will help accelerate its efforts to advance novel protein degrader therapeutics," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences said.
Through this named patient program in the Netherlands ('Leveren op Artsenverklaring'), physicians may seek individual access to TLX250-CDx for use in PET characterisation of renal masses as ccRCC. The first patient was dosed at Radboud University Medical Centre in Nijmegen, Netherlands.

By using this website you agree to accept Medical Device News Magazine Privacy Policy